News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Sales reflect continued strong growth in oncology and vaccines
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Subscribe To Our Newsletter & Stay Updated
